Immune Therapeutics (OTCMKTS:IMUND) Shares Up 2.9%

Immune Therapeutics, Inc. (OTCMKTS:IMUND – Get Rating)’s share price shot up 2.9% on Monday . The stock traded as high as $1.76 and last traded at $1.75. 600 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 1,650 shares. The stock had previously closed at $1.70.

The company has a 50 day moving average of $1.90 and a two-hundred day moving average of $2.15.

Immune Therapeutics Company Profile (OTCMKTS:IMUND)

Immune Therapeutics, Inc, a late development-stage biopharmaceutical company, focuses on the development, commercialization, and licensing of prescription medications for humans, animals, and pets worldwide. It develops low dose naltrexone and methionine encephalin therapies for human immunodeficiency virus (HIV) infections, autoimmune diseases, immune disorders, or cancer.

Further Reading

• Get a free copy of the StockNews.com research report on Immune Therapeutics (IMUND)
• Ride Out The Recession With These Dividend Kings 
• MarketBeat: Week in Review 6/13 – 6/17
• eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
• Honda’s Stock Continues To Fly Under The Radar
• Vuzix Stock Stays Optimistic

Want More Great Investing Ideas?